Result Analysis Of BRAF V600E Gene Mutation Using Molecular And Immunohistochemistry Detection In Acral Malignant Melanoma

Hermin Aminah Usman, Bethy Suryawathy Hernowo, Maringan Diapari Lumban Tobing, Reti Hindritiani

Abstract


Background and Objective: Detection of BRAF V­600E gene mutation in Malignant Melanoma (MM) is essential in offering anti BRAF targeted therapy for MM patients. Expression of BRAF V600E mutant protein detected using immunohistochemistry (IHC) is afforadble, rapid, and reliable. This study aimed to measure the sensitivity and specificity of IHC compared to BRAFV 600E immunoexpression by molecular detection.

Method: This study used paraffin block of acral MM patients to analyze BRAF V600E mutation status using anti BRAF V600E IHC compared to Real Time Polymerase Chain Reaction (RT PCR) which is a gold standard.

Result: In total, ninety six samples were tested using IHC and RT-PCR. RT-PCR showed that 15 (15.6%) samples were positive for BRAF V600E mutation. The sensitivity and specificity for IHC were 73.3% and 87.6% respectively. Concordance value of IHC was 85.4%. There were 10 false positives and 4 false negatives.

IHC staining may be applied as early detection of BRAFV600E mutation in MM patients that are going to receive anti BRAF targeted therapy.

Keywords:BRAF V600E, immunohistochemistry, melanoma, RT-PCR.


Full Text:

PDF (FULL TEXT)

References


Hong JW, Lee S, Kim DC, Kim KH, Song KH. Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. Annals dermatol. 2014;26:195-202.

Qiu T, Lu H, Guo L, Huang W, Ling Y, Shan L. Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Scientific Reports. 2015;5:9211.

Kim HK, Lee S, Kim K, Heo MH, Lee H, Cho J. Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Translational Oncol.2016;9 :557-64.

Asgari MM, Shen L, Sokil MM, Yeh I, Jorgenson E. Prognostics factors and survival in acral lentiginous melanoma. British J Dermatol. 2017 Aug;177:428-435.

Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. Asia-Pacific J Clin Oncol. 2016;12:403-8.

Thiel A, Moza M, Kytola S, Orpana A, Jahkola T, Hernberg M . Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol. 2015;46:169-75.

Marin C, Beauchet A, Capper D, Zimmermann U, Julié C, Ilie M. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives Pathol Lab Med. 2013;138:71-5.

Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol diag : JMD. 2013;15:94-100.

Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol.2015;8:15072-8.

Feller JK, Yang S, Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol.2013;26:414-20.

Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1. PatholInt. 2014;64:601-6.

Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH, 3rd, Longshore JW. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol. (2014) Nov;45(11):2281-93.

Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PP, Patel KP, Estrella JS. Utility of BRAF V600E immunohistochemistry expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. HumPathol. (2015) ;46(8):1101-10.

Yaman B, Kandiloglu G, Akalin T. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. Am J Dermatopathol. (2016) Feb;38(2):113-20.

Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. Oncotarget. (2017) Jan 31;8(5):8069-82.




DOI (PDF (FULL TEXT)): http://dx.doi.org/10.22034/APJCC.2018.3.3.1

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Asia Pacific Journal of Cancer Care


 

  

PORTICO

 

Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention